Ainos is shifting into a diversified medtech leader ready to push the fields of low-dose interferon, telehealth-friendly POCT devices, and SRNA-driven preventative medicine.
We bring nearly four decades of acumen and insight to the next wave of medtech innovation.
Scientific innovation is rooted in good science. We hold over 60 patents, active and pending, with many more in the works. We have conducted more than 60 interferon clinical trials.
SINCE 1984
Our history
1984
Founded on core technology of non-injectable interferon alpha
2003
Phase III Clinical Trial – "Treatment of Primary Sjogren’s Syndrome With Low-Dose Human Interferon Alfa Administered by the Oromucosal Route: Combine Phase III Results"
2013
Phase II Clinical Trial - "Low-dose interferon alpha as prophylaxis against viral respiratory illness: a double-blind, parallel controlled trial during an influenza pandemic year"
2014
Phase II Clinical Trial – "A Double-Blind Randomized Controlled Study to Evaluate the Efficacy of Low-Dose Oral Interferon-Alpha in Preventing Hepatitis C Relapse"
2015
Reorganized and emerged from Chapter 11 as a diversified healthcare enterprise, no debt
2016-2017
Received 3 U.S. patents, 1 Taiwan patent related to thrombocytopenia
2019-2020
Received 2 Taiwan patents, 1 China patent related to proprietary SMART pulsatile insulin infusion pump
2021
Begins our medtech transformation, acquires digital nose diagnostic technologies and 50+ patents, renames to Ainos, Inc, and changes stock symbol to AIMD
OUR PRODUCTS
Better patient outcomes begin with comfort and safety
Ainos SARS-CoV-2 Antigen Rapid Test Kit is Taiwan's first Covid-19 antigen test co-developed by its national defense, health research institution and a biotech company.
National Health Research Institutes, Taiwan
CONTACT US
United States:
8880 Rio San Diego Drive, Suite 800, San Diego, CA 92108
+1 (858) 869-2986
Taiwan:
10F-2, No. 66, Shengyi 5th Rd., Zhubei City, Hsinchu County 302 , Taiwan (R.O.C.)
